Regulation of cell signalling by uPAR

[1]  K. Aldape,et al.  FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. , 2009, Molecular cell.

[2]  V. Ellis,et al.  Regulation of urokinase receptor function and pericellular proteolysis by the integrin α5β1 , 2009, Thrombosis and Haemostasis.

[3]  P. Carmeliet,et al.  Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/progenitor cells. , 2009, The Journal of clinical investigation.

[4]  G. Mills,et al.  Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity. , 2009, Cancer research.

[5]  S. Russell,et al.  Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. , 2009, Cancer research.

[6]  M. Humphries,et al.  Linking integrin conformation to function , 2009, Journal of Cell Science.

[7]  V. Leksa,et al.  Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor. , 2008, Molecular biology of the cell.

[8]  K. Takeuchi,et al.  The absence of uPAR is associated with the progression of dermal fibrosis. , 2008, The Journal of investigative dermatology.

[9]  F. Blasi,et al.  uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro , 2008, Journal of Cell Science.

[10]  Judith Campisi,et al.  Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor , 2008, PLoS biology.

[11]  H. Chapman,et al.  Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with β1 integrins , 2008, Journal of Cell Science.

[12]  K. Cortese,et al.  Clathrin and LRP-1-Independent Constitutive Endocytosis and Recycling of uPAR , 2008, PloS one.

[13]  Y. Fujiyoshi,et al.  Electron crystallography of proteins in membranes. , 2008, Current opinion in structural biology.

[14]  R. Fässler,et al.  The role of integrin binding sites in fibronectin matrix assembly in vivo. , 2008, Current opinion in cell biology.

[15]  M. Ploug,et al.  The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. , 2008, Current medicinal chemistry.

[16]  A. Mazar.  Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy , 2008, Clinical Cancer Research.

[17]  A. Vararattanavech,et al.  Urokinase-type Plasminogen Activator Receptor Induces Conformational Changes in the Integrin αMβ2 Headpiece and Reorientation of Its Transmembrane Domains* , 2008, Journal of Biological Chemistry.

[18]  C. Marshall,et al.  uPAR promotes formation of the p130Cas–Crk complex to activate Rac through DOCK180 , 2008, The Journal of cell biology.

[19]  Xiaoyuan Chen,et al.  Imaging of Urokinase-Type Plasminogen Activator Receptor Expression Using a 64Cu-Labeled Linear Peptide Antagonist by microPET , 2008, Clinical Cancer Research.

[20]  J. Arribas,et al.  Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17 , 2008, Biological chemistry.

[21]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[22]  I. Pastan,et al.  PATE Gene Clusters Code for Multiple, Secreted TFP/Ly-6/uPAR Proteins That Are Expressed in Reproductive and Neuron-rich Tissues and Possess Neuromodulatory Activity* , 2008, Journal of Biological Chemistry.

[23]  Katerina Akassoglou,et al.  NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α , 2008, Nature.

[24]  J. Larsen,et al.  A Composite Role of Vitronectin and Urokinase in the Modulation of Cell Morphology upon Expression of the Urokinase Receptor* , 2008, Journal of Biological Chemistry.

[25]  M. Ploug,et al.  Structure and ligand interactions of the urokinase receptor (uPAR). , 2008, Frontiers in bioscience : a journal and virtual library.

[26]  S. Serratì,et al.  The plasminogen activation system in inflammation. , 2008, Frontiers in bioscience : a journal and virtual library.

[27]  G. Høyer-Hansen,et al.  Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. , 2008, Frontiers in bioscience : a journal and virtual library.

[28]  A. Eddy,et al.  Urokinase and its receptors in chronic kidney disease. , 2008, Frontiers in bioscience : a journal and virtual library.

[29]  Aamir Ahmad,et al.  Evolving role of uPA/uPAR system in human cancers. , 2008, Cancer treatment reviews.

[30]  Ning Li,et al.  Nudel binds Cdc42GAP to modulate Cdc42 activity at the leading edge of migrating cells. , 2008, Developmental cell.

[31]  N. Nagai,et al.  Urokinase-type plasminogen activator receptor (uPAR) augments brain damage in a murine model of ischemic stroke , 2008, Neuroscience Letters.

[32]  D. Shaw,et al.  Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes , 2008, Nature Structural &Molecular Biology.

[33]  P. Carmeliet,et al.  Modification of kidney barrier function by the urokinase receptor , 2008, Nature Medicine.

[34]  Y. Miyagi,et al.  Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. , 2007, Cancer research.

[35]  Enrico Gratton,et al.  Monomer–dimer dynamics and distribution of GPI-anchored uPAR are determined by cell surface protein assemblies , 2007, The Journal of cell biology.

[36]  M. Jo,et al.  uPAR induces epithelial–mesenchymal transition in hypoxic breast cancer cells , 2007, The Journal of cell biology.

[37]  S. Shetty,et al.  Regulation of Urokinase Receptor Expression by p53: Novel Role in Stabilization of uPAR mRNA , 2007, Molecular and Cellular Biology.

[38]  A. Andolfo,et al.  uPAR-induced cell adhesion and migration: vitronectin provides the key , 2007, The Journal of cell biology.

[39]  M. Ploug,et al.  Mapping of the Vitronectin-binding Site on the Urokinase Receptor , 2007, Journal of Biological Chemistry.

[40]  A. Gaultier,et al.  Urokinase receptor primes cells to proliferate in response to epidermal growth factor , 2007, Oncogene.

[41]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[42]  H. Allgayer,et al.  Analysis of Specific Transcriptional Regulators as Early Predictors of Independent Prognostic Relevance in Resected Colorectal Cancer , 2007, Clinical Cancer Research.

[43]  H. Chapman,et al.  Urokinase Receptors Are Required for α5β1 Integrin-mediated Signaling in Tumor Cells* , 2006, Journal of Biological Chemistry.

[44]  M. Yeager,et al.  Electron microscopy of integrins. , 2007, Methods in enzymology.

[45]  T. Ahn,et al.  LY-6K gene: a novel molecular marker for human breast cancer. , 2006, Oncology reports.

[46]  O. Liang,et al.  A Region in Urokinase Plasminogen Receptor Domain III Controlling a Functional Association with α5β1 Integrin and Tumor Growth* , 2006, Journal of Biological Chemistry.

[47]  M. Stack,et al.  Functional Relevance of Urinary-type Plasminogen Activator Receptor-α3β1 Integrin Association in Proteinase Regulatory Pathways* , 2006, Journal of Biological Chemistry.

[48]  P. McKeown-Longo,et al.  Urokinase-type Plasminogen Activator Receptor Regulates a Novel Pathway of Fibronectin Matrix Assembly Requiring Src-dependent Transactivation of Epidermal Growth Factor Receptor* , 2006, Journal of Biological Chemistry.

[49]  D. Shaw,et al.  Structure of Human Urokinase Plasminogen Activator in Complex with Its Receptor , 2006, Science.

[50]  T. Stradal,et al.  Protein complexes regulating Arp2/3-mediated actin assembly. , 2006, Current opinion in cell biology.

[51]  F. Blasi,et al.  An uncleavable uPAR mutant allows dissection of signaling pathways in uPA-dependent cell migration. , 2005, Molecular biology of the cell.

[52]  H. Allgayer,et al.  Combination Analysis of Activator Protein-1 Family Members, Sp1 and an Activator Protein-2α-Related Factor Binding to Different Regions of the Urokinase Receptor Gene in Resected Colorectal Cancers , 2005, Clinical Cancer Research.

[53]  R. Czekay,et al.  Domain 2 of the Urokinase Receptor Contains an Integrin-interacting Epitope with Intrinsic Signaling Activity , 2005, Journal of Biological Chemistry.

[54]  B. Han,et al.  Urokinase-type plasminogen activator system and breast cancer (Review). , 2005, Oncology reports.

[55]  H. Haller,et al.  Urokinase‐induced signaling in human vascular smooth muscle cells is mediated by PDGFR‐β , 2005, The EMBO journal.

[56]  A. Ménez,et al.  Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide , 2005, The EMBO journal.

[57]  F. Werner,et al.  Regulation of Urokinase Receptor Proteolytic Function by the Tetraspanin CD82* , 2005, Journal of Biological Chemistry.

[58]  S. Shetty.  Regulation of urokinase receptor mRNA stability by hnRNP C in lung epithelial cells , 2005, Molecular and Cellular Biochemistry.

[59]  L. Lund,et al.  Plasminogen activation and cancer , 2005, Thrombosis and Haemostasis.

[60]  B. Nielsen,et al.  Reduced metastasis of transgenic mammary cancer in urokinase‐deficient mice , 2005, International journal of cancer.

[61]  Karen D. Cowden Dahl,et al.  Hypoxia-inducible factor regulates alphavbeta3 integrin cell surface expression. , 2005, Molecular biology of the cell.

[62]  Erik Sahai,et al.  Mechanisms of cancer cell invasion. , 2005, Current opinion in genetics & development.

[63]  J. Xiong,et al.  Regulation of α5β1 integrin conformation and function by urokinase receptor binding , 2005, The Journal of cell biology.

[64]  M. Maruyama,et al.  Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators , 1996, Inflammation.

[65]  G. Marone,et al.  Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 21 , 2004, The Journal of Immunology.

[66]  M. Cinelli,et al.  Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvascular endothelial cells results in impaired angiogenesis. , 2004, Arthritis and rheumatism.

[67]  W. Weichert,et al.  Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma , 2004, Clinical Cancer Research.

[68]  S. Steurer,et al.  Vascular Endothelial Growth Factor Receptor-2–Induced Initial Endothelial Cell Migration Depends on the Presence of the Urokinase Receptor , 2004, Circulation research.

[69]  M. Stratton,et al.  The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website , 2004, British Journal of Cancer.

[70]  E. Żekanowska,et al.  Urokinase plasminogen activator (uPA) and its receptor (uPAR) in gestational tissues; Measurements and clinical implications. , 2004, European journal of obstetrics, gynecology, and reproductive biology.

[71]  T. Möröy,et al.  Identification of Tcf-4 as a transcriptional target of p53 signalling , 2004, Oncogene.

[72]  Finn Werner,et al.  Characterization of low-glycosylated forms of soluble human urokinase receptor expressed in Drosophila Schneider 2 cells after deletion of glycosylation-sites. , 2004, Protein expression and purification.

[73]  A. Órfão,et al.  CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review , 2004, Leukemia.

[74]  P. McKeown-Longo,et al.  The Receptor for Urokinase-type Plasminogen Activator Regulates Fibronectin Matrix Assembly in Human Skin Fibroblasts* , 2004, Journal of Biological Chemistry.

[75]  W. Weichert,et al.  Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression , 2004, Cancer Research.

[76]  M. Jo,et al.  Soluble Urokinase-type Plasminogen Activator Receptor Inhibits Cancer Cell Growth and Invasion by Direct Urokinase-independent Effects on Cell Signaling* , 2003, Journal of Biological Chemistry.

[77]  F. Blasi,et al.  Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions , 2003, The EMBO journal.

[78]  Laure Plantard,et al.  Identification of SLURP-1 as an epidermal neuromodulator explains the clinical phenotype of Mal de Meleda. , 2003, Human molecular genetics.

[79]  J. Brugge,et al.  Src kinase activation by direct interaction with the integrin β cytoplasmic domain , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[80]  Y. Nagamine,et al.  Stabilization of Urokinase and Urokinase Receptor mRNAs by HuR Is Linked to Its Cytoplasmic Accumulation Induced by Activated Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 , 2003, Molecular and Cellular Biology.

[81]  T. Ching,et al.  Distinct ligand binding sites in integrin α3β1 regulate matrix adhesion and cell–cell contact , 2003, The Journal of cell biology.

[82]  C. Isacke,et al.  GPI-anchored uPAR requires Endo180 for rapid directional sensing during chemotaxis , 2003, The Journal of cell biology.

[83]  Erik Sahai,et al.  Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis , 2003, Nature Cell Biology.

[84]  N. Brünner,et al.  Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice , 2003, Oncogene.

[85]  E. Sahai,et al.  ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility. , 2003, Cancer cell.

[86]  P. Carmeliet,et al.  Urokinase receptor modulates cellular and angiogenic responses in obstructive nephropathy. , 2003, Journal of the American Society of Nephrology : JASN.

[87]  P. Carmeliet,et al.  J Am Soc Nephrol 14: 1254–1271, 2003 Urokinase Receptor Deficiency Accelerates Renal Fibrosis in Obstructive Nephropathy , 2022 .

[88]  G. Semenza,et al.  Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.

[89]  M. Jo,et al.  Epidermal Growth Factor Receptor-dependent and -independent Cell-signaling Pathways Originating from the Urokinase Receptor* , 2003, The Journal of Biological Chemistry.

[90]  S. L. Gonias,et al.  Regulation of Rac1 activation by the low density lipoprotein receptor–related protein , 2002, The Journal of cell biology.

[91]  S. Salzano,et al.  The Cleavage of the Urokinase Receptor Regulates Its Multiple Functions* , 2002, The Journal of Biological Chemistry.

[92]  H. Petty,et al.  Function of the Lectin Domain of Mac-1/Complement Receptor Type 3 (CD11b/CD18) in Regulating Neutrophil Adhesion1 , 2002, The Journal of Immunology.

[93]  P. Carmeliet,et al.  uPAR: a versatile signalling orchestrator , 2002, Nature Reviews Molecular Cell Biology.

[94]  Satoshi Matsumoto,et al.  Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.

[95]  C. Isacke,et al.  The C-type Lectin Receptor Endo180 Displays Internalization and Recycling Properties Distinct from Other Members of the Mannose Receptor Family* , 2002, The Journal of Biological Chemistry.

[96]  F. Blasi,et al.  Urokinase Regulates Vitronectin Binding by Controlling Urokinase Receptor Oligomerization* , 2002, The Journal of Biological Chemistry.

[97]  F. Blasi,et al.  Metalloproteases Cleave the Urokinase-Type Plasminogen Activator Receptor in the D1-D2 Linker Region and Expose Epitopes not Present in the intact Soluble Receptor , 2002, Thrombosis and Haemostasis.

[98]  L. Ossowski,et al.  EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. , 2002, Cancer cell.

[99]  J. Foekens,et al.  Differential Effects of Fibroblast Growth Factors on Expression of Genes of the Plasminogen Activator and Insulin-like Growth Factor Systems by Human Breast Fibroblasts , 2002, Thrombosis and Haemostasis.

[100]  P. Carmeliet,et al.  Urokinase Receptor Is Necessary for Adequate Host Defense Against Pneumococcal Pneumonia1 , 2002, The Journal of Immunology.

[101]  Ji Ming Wang,et al.  The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[102]  J. Aguirre Ghiso.  Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo , 2002, Oncogene.

[103]  E. Goldsmith,et al.  Serpins and other covalent protease inhibitors. , 2001, Current opinion in structural biology.

[104]  J. Curtis,et al.  Cutting Edge: Antigen-Driven Lymphocyte Recruitment to the Lung Is Diminished in the Absence of Urokinase-Type Plasminogen Activator (uPA) Receptor, but Is Independent of uPA1 , 2001, The Journal of Immunology.

[105]  R. Czekay,et al.  Plasminogen activator inhibitor‐1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin , 2001, Journal of cellular physiology.

[106]  J. Kreidberg,et al.  Urokinase Receptors Promote β1 Integrin Function through Interactions with Integrin α3β1 , 2001 .

[107]  R. Czekay,et al.  Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. , 2001, Molecular biology of the cell.

[108]  D. Woods,et al.  Induction of β3-Integrin Gene Expression by Sustained Activation of the Ras-Regulated Raf–MEK–Extracellular Signal-Regulated Kinase Signaling Pathway , 2001, Molecular and Cellular Biology.

[109]  J. Aguirre-Ghiso,et al.  Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. , 2001, Molecular biology of the cell.

[110]  A. Hall,et al.  Rac Mediates Cytoskeletal Rearrangements and Increased Cell Motility Induced by Urokinase-Type Plasminogen Activator Receptor Binding to Vitronectin , 2001, The Journal of cell biology.

[111]  A. Mazar,et al.  Urokinase-type Plasminogen Activator Receptor (CD87) Is a Ligand for Integrins and Mediates Cell-Cell Interaction* , 2001, The Journal of Biological Chemistry.

[112]  B. Nielsen,et al.  The Murine Receptor for Urokinase-Type Plasminogen Activator Is Primarily Expressed in Tissues Actively Undergoing Remodeling , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[113]  J. Schwab,et al.  Lesion‐associated accumulation of uPAR/CD87‐ expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans , 2000, Neuropathology and applied neurobiology.

[114]  E. Dublin,et al.  Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. , 2000, The American journal of pathology.

[115]  T. Standiford,et al.  Urokinase Receptor-Deficient Mice Have Impaired Neutrophil Recruitment in Response to Pulmonary Pseudomonas aeruginosa Infection1 , 2000, The Journal of Immunology.

[116]  Donna J. Webb,et al.  Urokinase-type Plasminogen Activator Stimulates the Ras/Extracellular Signal-regulated Kinase (ERK) Signaling Pathway and MCF-7 Cell Migration by a Mechanism That Requires Focal Adhesion Kinase, Src, and Shc , 2000, The Journal of Biological Chemistry.

[117]  F. Blasi,et al.  Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo , 2000, FEBS letters.

[118]  H. Allgayer,et al.  Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. , 2000, European journal of biochemistry.

[119]  S. Rosenberg,et al.  Identification of a Urokinase Receptor-Integrin Interaction Site , 2000, The Journal of Biological Chemistry.

[120]  A. Krüger,et al.  Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87) , 2000, Cancer Gene Therapy.

[121]  M. Mann,et al.  A Urokinase Receptor-associated Protein with Specific Collagen Binding Properties* , 2000, The Journal of Biological Chemistry.

[122]  D. Webb,et al.  Extracellular signal-regulated kinase functions in the urokinase receptor-dependent pathway by which neutralization of low density lipoprotein receptor-related protein promotes fibrosarcoma cell migration and matrigel invasion. , 2000, Journal of cell science.

[123]  L. Sunde,et al.  Localization and significance of urokinase plasminogen activator and its receptor in placental tissue from intrauterine, ectopic and molar pregnancies. , 1999, Placenta.

[124]  G. D'aiuto,et al.  Urokinase Receptor Interacts with αvβ5 Vitronectin Receptor, Promoting Urokinase-dependent Cell Migration in Breast Cancer , 1999 .

[125]  L. Ossowski,et al.  Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling , 1999, The Journal of cell biology.

[126]  D. Rifkin,et al.  Cellular glycosylphosphatidylinositol‐specific phospholipase D regulates urokinase receptor shedding and cell surface expression , 1999, Journal of cellular physiology.

[127]  S. L. Gonias,et al.  Myosin Light Chain Kinase Functions Downstream of Ras/ERK to Promote Migration of Urokinase-Type Plasminogen Activator-Stimulated Cells in an Integrin-Selective Manner , 1999, The Journal of cell biology.

[128]  H. Chapman,et al.  A Role for Caveolin and the Urokinase Receptor in Integrin-mediated Adhesion and Signaling , 1999, The Journal of cell biology.

[129]  W F Bodmer,et al.  Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[130]  K. Preissner,et al.  Urokinase Receptor (CD87) Regulates Leukocyte Recruitment via β2 Integrins In Vivo , 1998, The Journal of experimental medicine.

[131]  B. Casslén,et al.  Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. , 1998, Cancer research.

[132]  B. Nielsen,et al.  Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice , 1998, Oncogene.

[133]  P. Roepstorff,et al.  Glycosylation Profile of a Recombinant Urokinase-type Plasminogen Activator Receptor Expressed in Chinese Hamster Ovary Cells* , 1998, The Journal of Biological Chemistry.

[134]  F. Hucho,et al.  Downstream targets of urokinase-type plasminogen-activator-mediated signal transduction. , 1998, European journal of biochemistry.

[135]  K. Preissner,et al.  The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction , 1997, FEBS letters.

[136]  P. Carmeliet,et al.  Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation , 1997, Nature Genetics.

[137]  P. Hufnagl,et al.  Urokinase Receptor Is Associated with the Components of the JAK1/STAT1 Signaling Pathway and Leads to Activation of This Pathway upon Receptor Clustering in the Human Kidney Epithelial Tumor Cell Line TCL-598* , 1997, The Journal of Biological Chemistry.

[138]  F. Blasi,et al.  Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.

[139]  H. Petty,et al.  Urokinase-Type Plasminogen Activator Receptors Associate with β1 and β3 Integrins of Fibrosarcoma Cells: Dependence on Extracellular Matrix Components , 1997 .

[140]  M. Ploug,et al.  Cell-surface acceleration of urokinase-catalyzed receptor cleavage. , 1997, European journal of biochemistry.

[141]  O. Majdic,et al.  Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. , 1996, Blood.

[142]  D. Boyd,et al.  Requirement of an Upstream AP-1 Motif for the Constitutive and Phorbol Ester-inducible Expression of the Urokinase-type Plasminogen Activator Receptor Gene* , 1996, The Journal of Biological Chemistry.

[143]  Michael V. Doyle,et al.  Regulation of Integrin Function by the Urokinase Receptor , 1996, Science.

[144]  D. Loskutoff,et al.  Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? , 1996, The Journal of cell biology.

[145]  M. Gyetko,et al.  The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. , 1996, The Journal of clinical investigation.

[146]  R. Pardi,et al.  alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)- dependent internalization of the urokinase receptor , 1995, The Journal of cell biology.

[147]  T. Standiford,et al.  Function of the urokinase receptor (CD87) in neutrophil Chemotaxis , 1995, Journal of leukocyte biology.

[148]  E. Lengyel,et al.  Involvement of a Mitogen-activated Protein Kinase Signaling Pathway in the Regulation of Urokinase Promoter Activity by c-Ha-ras(*) , 1995, The Journal of Biological Chemistry.

[149]  O. Majdic,et al.  Urokinase plasminogen activator receptor, beta 2-integrins, and Src- kinases within a single receptor complex of human monocytes , 1995, The Journal of experimental medicine.

[150]  S. Rosenberg,et al.  Identification of the urokinase receptor as an adhesion receptor for vitronectin. , 1994, The Journal of biological chemistry.

[151]  T. Hunter,et al.  Integrin-mediated signal transduction linked to Ras pathway by GRB2 binding to focal adhesion kinase , 1994, Nature.

[152]  H. Johnsen,et al.  Expression of the receptor for urokinase-type plasminogen activator in normal and neoplastic blood cells and hematopoietic tissue. , 1994, American journal of clinical pathology.

[153]  M. Ploug,et al.  Structure—function relationships in the receptor for urokinase‐type plasminogen activator Comparison to other members of the Ly‐6 family and snake venom α‐neurotoxins , 1994 .

[154]  S. Waxman,et al.  Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells , 1994, The Journal of cell biology.

[155]  H. Petty,et al.  Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. , 1994, Journal of immunology.

[156]  L. Lund,et al.  The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds. , 1994, The Journal of investigative dermatology.

[157]  M. Gyetko,et al.  The urokinase receptor is required for human monocyte chemotaxis in vitro. , 1994, The Journal of clinical investigation.

[158]  L. Kirkeby,et al.  Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer , 1994, Histopathology.

[159]  P. Andreasen,et al.  Urokinase receptor. An activation antigen in human T lymphocytes. , 1994, Journal of immunology.

[160]  U. Weidle,et al.  Recombinant soluble urokinase receptor as a scavenger for urokinase‐type plasminogen activator (uPA) , 1994, FEBS letters.

[161]  D. Cheresh,et al.  Vitronectin and its receptors. , 1993, Current opinion in cell biology.

[162]  A. Vaheri,et al.  Distribution and lateral mobility of the urokinase-receptor complex at the cell surface. , 1993, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[163]  F. Blasi,et al.  N-linked glycosylation of the ligand-binding domain of the human urokinase receptor contributes to the affinity for its ligand. , 1993, The Journal of biological chemistry.

[164]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[165]  L. Lund,et al.  Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. , 1992, The Journal of biological chemistry.

[166]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[167]  M. Ploug,et al.  Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. , 1992, European journal of biochemistry.

[168]  D. Cheresh,et al.  Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. , 1991, The Journal of clinical investigation.

[169]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[170]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[171]  H. Chapman,et al.  An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. , 1991, The Journal of clinical investigation.

[172]  F. Blasi,et al.  Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. , 1991, The Journal of biological chemistry.

[173]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[174]  E. Appella,et al.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. , 1990, The Journal of biological chemistry.

[175]  H. Moses,et al.  Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin , 1990, The Journal of cell biology.

[176]  H. Moses,et al.  Mechanism of Activation of Latent Recombinant Transforming Growth Factor by Plasmin , 2002 .

[177]  D. Belin,et al.  Characterization of the cellular binding site for the urokinase-type plasminogen activator. , 1989, The Journal of biological chemistry.

[178]  P. Vielh,et al.  Comparative distribution of fibronectin and vitronectin in human breast and colon carcinomas. An immunofluorescence study. , 1988, American journal of clinical pathology.

[179]  J. Zeuthen,et al.  Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. , 1982, Biochemistry.